![Is Puma off the cancer M&A list? With Nerlyx marketing deal, some investors think so | Fierce Pharma Is Puma off the cancer M&A list? With Nerlyx marketing deal, some investors think so | Fierce Pharma](https://qtxasset.com/quartz/qcloud5/media/image/fiercepharma/1554213706/Pumalounging.jpg/Pumalounging.jpg?VersionId=AXzRJpBb66kBzE1ipO.16_8WJAXmXjo2)
Is Puma off the cancer M&A list? With Nerlyx marketing deal, some investors think so | Fierce Pharma
![Puma Biotechnology and Bixink Therapeutics Enter into Exclusive Licensing Agreement to Commercialize NERLYNX® (neratinib) in South Korea | Business Wire Puma Biotechnology and Bixink Therapeutics Enter into Exclusive Licensing Agreement to Commercialize NERLYNX® (neratinib) in South Korea | Business Wire](https://mms.businesswire.com/media/20200430005669/en/305625/23/puma_logo_JPEG.jpg)
Puma Biotechnology and Bixink Therapeutics Enter into Exclusive Licensing Agreement to Commercialize NERLYNX® (neratinib) in South Korea | Business Wire
![Puma Biotechnology Reports Results of Neratinib (PB272) in P-III NALA Trial for 3L HER2-Positive Metastatic Breast Cancer Puma Biotechnology Reports Results of Neratinib (PB272) in P-III NALA Trial for 3L HER2-Positive Metastatic Breast Cancer](https://pharmashots.com/public/images/20211115201406_ogImage_7.jpg)
Puma Biotechnology Reports Results of Neratinib (PB272) in P-III NALA Trial for 3L HER2-Positive Metastatic Breast Cancer
![Puma Biotech Strikes Deal to Develop and Market its Breast Cancer Drug in China - Los Angeles Business Journal Puma Biotech Strikes Deal to Develop and Market its Breast Cancer Drug in China - Los Angeles Business Journal](https://d3evu7qlt2vui6.cloudfront.net/wp-content/uploads/2021/11/1700082801d.jpg)